26 - 30 May 2018
Munich, Germany

Industry Programme

Satellite Symposia

Sunday, 27 May 2018


Company Sponsored Satellite Symposium (SAT1)
DBV Technologies
17:30 – 19:00, Hall 14a
 

A Closer Look at the Burden of Peanut Allergy and Its Potential Management

Chairs: Antonella Maria Muraro, Italy
Hugh A. Sampson, United States

Welcome and Introductions
Hugh A. Sampson, United   States

The Medical Burden of Peanut Allergy in Europe
Susanne Lau, Germany

Living With Peanut Allergy: the Patient and Caregiver Perspective
George du Toit, United Kingdom

A Review of Investigational Epicutaneous Immunotherapy for Peanut Allergy
Frédéric de Blay, France

Summary
Antonella Maria Muraro, Italy

Faculty Panel Q&A
All Faculty

Company Sponsored Satellite Symposium (SAT2)
FAES FARMA & MENARINI GROUP
17:30 – 19:00, Hall 14c
 

Bilastine: A Lifetime Companion for the Treatment of Allergies

Chairs: Marysia Recto, Philippines
Giorgio Walter Canonica, Italy

Bilastine in school-age children
Nikolaos Papadopoulos, Greece

Bilastine in adults with allergic rhinitis
Ralph Mösges, Germany

Bilastine in adults with urticaria and skin diseases
Martin Church, Germany

Bilastine in seniorhood: a multi-faced antihistamine
Erminia Ridolo, Italy

Company Sponsored Satellite Symposium (SAT3)       
Allergy Therapeutics plc.
17:30 – 19:00, Hall 13a
Allergy Logo transparent 
 
Adjuvants through the ages

Adjuvants in allergy
Carsten Schmidt-Weber, Germany

Mode of action of adjuvants in allergoid immunotherapy
Thomas Kuendig, Switzerland

Using Virus-like particles for peanut allergy
Martin Bachmann, Switzerland



 

Company Sponsored Satellite Symposium (SAT4) GlaxoSmithKline
17:30 – 19:00, Hall 13b
 

Effectiveness studies: Critical data to help understand how medicines really work?

Chair: Joachim Lorenz, Germany

Chair’s welcome
Joachim Lorenz, Germany

Raising the bar: Are we meeting the needs of asthma patients now and in the future?
Monica Fletcher, United Kingdom

What powers effectiveness in asthma treatments?
Neil Barnes, United Kingdom

RCTs are the gold standard, why do we need effectiveness studies?
Andreas Heddini , United Kingdom

The Salford Lung Study: Cutting edge effectiveness research
Dave Leather, United Kingdom

Q&A and closing remarks
Joachim Lorenz, Germany


Company Sponsored Satellite Symposium (SAT5)        
Sanofi Genzyme and Regeneron
17:30 – 19:00, Hall E
 

Comorbidities in Atopic Dermatitis: Impact Beyond the Skin

Chair: Donald Leung, United States

Welcome and Introduction
Donald Leung, United States

The Systemic Burden of Allergic Diseases: Focus on Atopic Dermatitis
Peter Schmid-Grendelmeier, Switzerland

Type 2 Immunity in the Pathophysiology of Atopic Dermatitis and Other Atopic Diseases
Donald Leung, United States

Clinical Data and Treatment Strategies for Patients With Atopic Dermatitis and Atopic Comorbidities: Should Complex Allergic Diseases Be Managed by a Multidisciplinary Approach?
Diamant Thaci, Germany

Closing Remarks and Panel Q&A
All


Company Sponsored Satellite Symposium (SAT6)
URIACH
17:30 – 19:00, Hall 5
Marca Uriach Pantone

The needs of allergic patients and how to address them          Livestreaming Session


Chair: Marcus Maurer, Germany

Chair’s welcome and introduction
Marcus Maurer, Germany

Matching the ARIA guidelines to new technologies
Jean Bousquet, France

Rupatadine in allergic rhinitis: a treatment for all patient types
Susan Waserman, Canada

Rupatadine in dermatology, beyond urticaria
Masatoshi Abe, Japan

Discussion and conclusions
Marcus Maurer, Germany



Company Sponsored Satellite Symposium (SAT7)
Shire International GmbH
17:30 – 19:00, Hall B

 

Shaping the future of hereditary angioedema: improving patient outcomes

Chair: Hilary Longhurst, United Kingdom

Welcome and introduction to hereditary angioedema (HAE)
Hilary Longhurst, United Kingdom

HAE management recommendations: a physician and patient perspective
Hilary Longhurst, United Kingdom/Markus Magerl, Germany/Henrik Balle Boysen, Denmark

Recent advances in the management of paediatric HAE
Hilary Longhurst, United Kingdom/Markus Magerl, Germany

HAE management: what does the future hold?
Hilary Longhurst, United Kingdom/Markus Magerl, Germany

Q&A and closing remarks
Hilary Longhurst, United Kingdom/Markus Magerl, Germany


 
Monday, 28 May 2018


Company Sponsored Satellite Symposium (SAT8)
Nestlé Health Science
17:45 – 19:15, Hall 14a

 

Towards an Optimised Management of Cow’s Milk Protein Allergy
  
Chair: Philippe Eigenmann, Switzerland   

How to Define Extensively Hydrolysed Formula for the Management of Cow’s Milk Protein Allergy
Sophie Nutten, Switzerland 

Knowledge Gaps in Diagnosing and Managing Cow’s Milk Protein Allergy
Armando Madrazo, Mexico

The Gut Microbiome and its Role in Early Immune Development and Allergies
Liam O’Mahoney, Switzerland



Company Sponsored Satellite Symposium (SAT9)
Sanofi Genzyme and Regeneron
17:45 – 19:15, Hall 13a


Raising the Clinical Bar Beyond Current Biologics in Uncontrolled Persistent Asthma: Translating Emerging Data in Future Clinical Decisions     Livestreaming Session

Welcome and Introduction
Klaus Rabe, Germany

Heterogeneity of Type 2 Inflammation in Asthma: Biomarkers and Pathways
William Busse, United States

Current Clinical Approaches and Challenges in Management of Uncontrolled Persistent Asthma
Ian Pavord, United Kingdom

Expert Insight into Emerging Clinical Data and Implications for Future Clinical Decision-Making and Clinical Practice in Uncontrolled Persistent Asthma Mario Castro, United States

Closing Remarks and Panel Q&A
Klaus Rabe, Germany

Company Sponsored Satellite Symposium (SAT10)
CSL Behring
17:45 – 19:15, Hall 13b
 

Adressing the burden of hereditary angioedema (HAE)

Chairs: Konrad Bork, Germany
Peter Schmid-Grendelmeier, Switzerland

Welcome and introductions; The burden of HAE
Konrad Bork, Timothy Craig

Current options for the management of HAE
Markus Magerl, Germany

How subcutaneous C1-INH replacement therapy addresses the burden of HAE
Bruce L Zuraw, United States

Management of severe HAE with C1-INH (SC): a patient perspective
Donald S. Levy, HAE patient

Question and answer session
All speakers



Company Sponsored Satellite Symposium (SAT11)
GlaxoSmithKline
17:45 – 19:15, Hall A

 

Treating severe eosinophilic asthma patients with overlapping phenotypes

Chairs: Neil Barnes, United Kingdom
Hubert Hautmann, Germany

Chair’s welcome
Neil Barnes, GSK, United Kingdom

One patient, two phenotypes, what’s a doc to do?
Emilio Pizzichini, GSK, Brazil

Blood eosinophils: A predictor of response
Neil Barnes, GSK, United Kingdom

Making the switch to mepolizumab in patients with severe asthma
Ken Chapman, GSK, Canada

Start or stop? Strategy for patient selection
Neil Martin, GSK, United Kingdom

Q&A and closing remarks
Neil Barnes, GSK, United Kingdom/Hubert Hautmann, Germany


Company Sponsored Satellite Symposium (SAT12)
LABORATORIOS LETI S.L.
17:45 – 19:15, Hall B
 1 20COLOR


Research in AIT: focus on patient’s needs      Livestreaming Session

Classical approach in AIT research
Ralph Mösges, Germany

Shortcomings of the classical approach and recommendations for future research in AIT
Oliver Pfaar, Germany

Personalised medicine in AIT
Pablo Rodriguez, Spain


 

Company Sponsored Satellite Symposium (SAT13)
Aimmune Therapeutics
17:45 – 19:15, Hall C
 

Immunotherapy for Food Allergy Management: Evolution or Revolution?


Video Introduction
Stephen Holgate, United Kingdom

The challenges of current food allergy management
Antonella Maria Muraro, Italy

What are the recent advances in food allergy management?
Jonathan Hourihane, Ireland

How do the recent advances affect the clinical care of peanut allergy?
Maria Montserrat Fernandez-Rivas, Spain

Who are the optimal patients for peanut allergy immunotherapy?
George du Toit, United Kingdom

Panel discussion


Tuesday, 29 May 2018

 


Company Sponsored Satellite Symposium (SAT14)
Sanofi Genzyme and Regeneron
17:30 – 19:00, Hall A

 

Clinical Considerations in Chronic Rhinosinusitis with Nasal Polyps - Current and Future Directions in Disease Management: The Misery, Mystery, and Mastery       Livestreaming Session

Chair: Claus Bachert, Belgium

Welcome and Introduction
Claus Bachert, Belgium

The MISERY: Current Treatments and Limitations in CRSwNP
Philippe Gevaert, Belgium

The MYSTERY: Pathophysiology of CRSwNP and Type 2 Cytokines
Martin Desrosiers, Canada

The MASTERY: Biologic Management of CRSwNP
Joaquim Mullol, Spain

Closing Remarks and Panel Q&A
Claus Bachert, Belgium